Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Elanco Animal Health, Dow AgroSciences Announce Strategic R&D Agreement

By Pharmaceutical Processing | September 18, 2014

Elanco, the animal health division of Eli Lilly and Company, and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, are announcing a strategic research and development (R&D) agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.

According to the U.N. Food and Agriculture Organization (FAO), demand for meat, milk, and eggs will increase by more than 60 percent in the next few decades. The agreement leverages the strengths of Elanco’s animal health business with the proprietary germplasm and feed technologies of Dow AgroSciences to develop innovative solutions that can increase the efficiency, quality, and productivity of livestock for ranchers and producers worldwide.

“Dow AgroSciences is proud to work closely with another Indiana agricultural company to develop future product solutions for beef and dairy producers,” says Tim Hassinger, President and CEO, Dow AgroSciences. “Collaborating with Elanco is exciting because it unites the strength of their animal health expertise with our feed and forage expertise. Together, we will be looking for ways to develop total solutions that involve improving both the carrying capacity of the land and the health and productivity of production animals to help our customers meet the needs of the growing world.”

“Delivering enough of the high quality meat, milk and eggs we’ll need to feed our growing population is one of the greatest challenges of our time,” said Jeff Simmons, President of Elanco. “And we’ll have to produce more with less because we are already over using our resources, equivalent to 1.5 earths each year. Ultimately, these issues will be solved with innovative solutions, which is at the foundation of this agreement. We are very excited about the opportunities this effort will bring.”

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE